Clinical Cancer Cytogenetics

NCI/CCR/LP临床细胞遗传学科的使命是为在Mark O接受评估和治疗的患者提供最先进的诊断服务。哈特菲尔德临床研究中心;参与合作临床转化研究;并在临床细胞遗传学服务和研究的原则和实践方面教授和指导学生，居民和研究员。该项目的目标，其中包括85%的部分的努力，是提供诊断服务和研究测试的样本从病人进入临床研究协议由NCI和其他研究所医生，临床转化研究协议的合作，并教导和指导学生，居民，和研究员。临床细胞遗传学科是唯一的内部NIH实验室进行细胞遗传学诊断服务。该实验室由美国病理学家学院、医疗保健组织认证联合委员会和1988年临床实验室改进法案进行检查和认证。我们目前对来自许多研究所（NCI，NIAID，NHLBI，NHGRI，NIAMS，NIDDK和NICHD）和临床中心实验室医学部的患者样本进行高度复杂的常规和分子细胞遗传学检测。在99%的情况下，测试是为获得性染色体异常的癌前病变和恶性疾病，并在其余的1%的情况下，是为宪法染色体异常。我们的测试结果用于患者的诊断，分类，预后和治疗计划。它们还提供了关于基因区域的关键信息，这些基因区域可能对肿瘤的发生和发展很重要，因此可以作为恶性疾病进一步分子生物学研究的起点。部门成员正在对参加NCI和NHLBI临床研究方案的患者进行常规诊断和研究荧光分析。亚瑟博士是11个NCI和3个NHLBI活动方案的副研究员。作为这些研究的一部分生成的细胞遗传学数据在临床上可用于患者的诊断、分类和治疗分配。它们对于监测患者对实验治疗的反应以及与其他研究的相关性也很重要。它们有可能发现这些疾病之间新的临床病理学关联，以及可能成为未来治疗目标的生物学机制。最后，部分成员教导和指导学生，居民和研究员在临床细胞遗传学服务和研究的原则和实践。除了指导四名暑期学生和两名博士后研究员，亚瑟博士是NCI/CCR/LP居民和NCI/CCR/LP血液病理学研究员学院的成员。在这个角色中，她为所有参加这些培训项目的居民和研究员提供教学讲座和实验室轮换。总之，临床癌症细胞遗传学计划为LP和CCR提供独特的最先进的临床细胞遗传学服务，必要的教育和服务，并为NCI临床和转化研究计划提供广泛的合作支持。

The mission of the NCI/CCR/LP Clinical Cytogenetics Section is to provide state-of-the-art diagnostic services for patients evaluated and treated at the Mark O. Hatfield Clinical Research Center; to participate in collaborative clinical translational research; and to teach and mentor students, residents, and fellows in the principles and practices of clinical cytogenetics service and research. The goals of this project, which comprises 85 percent of the effort of the section, are to provide diagnostic service and research testing on samples from patients entered on clinical research protocols by NCI and other Institute physicians, to collaborate on clinical translational research protocols, and to teach and mentor students, residents, and fellows. The Clinical Cytogenetics Section is the only intramural NIH laboratory performing cytogenetics diagnostic services. The laboratory is inspected and certified by the College of American Pathologists, the Joint Commission for Accreditation of Healthcare Organizations, and the Clinical Laboratory Improvement Act of 1988. We currently perform highly complex routine and molecular cytogenetic testing on patient samples from a number of institutes (NCI, NIAID, NHLBI, NHGRI, NIAMS, NIDDK, and NICHD) and the Clinical Center Department of Laboratory Medicine. In 99 percent of cases the testing is for acquired chromosome abnormalities in premalignant and malignant disorders, and in the remaining 1 percent of cases is for constitutional chromosome abnormalities. The results of our testing are used for diagnosis, classification, prognosis, and treatment planning for patients. They also provide critical information regarding the gene regions that may be important for tumor initiation and progression, and thus serve as a starting point for further molecular biologic investigations of malignant diseases. Section members are conducting routine diagnostic and research fluorescence analyses of patients entered on NCI and NHLBI clinical research protocols. Dr. Arthur is an Associate Investigator on 11 NCI and three NHLBI active protocols. The cytogenetics data generated as part of these studies are clinically useful for diagnosis, classification, and treatment assignment for patients. They are also important for monitoring patient response to experimental therapy, and for correlation with other research studies. They have the potential for discovery of new clinical-pathological associations among these diseases and of biological mechanisms that may be targeted with future therapies. Finally, section members teach and mentor students, residents, and fellows in the principles and practices of clinical cytogenetics service and research. In addition to mentoring four summer students and two postdoctoral fellows, Dr. Arthur is a member of the NCI/CCR/LP Resident and NCI/CCR/LP Hematopathology Fellow faculties. In this role, she provides didactic lectures and laboratory rotations for all residents and fellows enrolled in these training programs. In summary, the Clinical Cancer Cytogenetics program provides unique state-of-the-art clinical cytogenetics service, essential education and service to the LP and the CCR, and wide collaborative support for NCI clinical and translational research programs.